Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective
出版年份 2023 全文链接
标题
Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective
作者
关键词
-
出版物
ANNALS OF PHARMACOTHERAPY
Volume -, Issue -, Pages 106002802211468
出版商
SAGE Publications
发表日期
2023-01-14
DOI
10.1177/10600280221146878
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities
- (2021) Briana M. Choi et al. JOURNAL OF MEDICAL ECONOMICS
- Systemic Therapy for Melanoma: ASCO Guideline
- (2020) Rahul Seth et al. JOURNAL OF CLINICAL ONCOLOGY
- Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing
- (2020) Nimer S. Alkhatib et al. JOURNAL OF MEDICAL ECONOMICS
- The six Delta platform for outcome-based contracting for pharmaceuticals
- (2020) Nimer S. Alkhatib et al. JOURNAL OF MEDICAL ECONOMICS
- Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma
- (2019) F. Consoli et al. Clinical & Translational Oncology
- Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review
- (2019) Claire Gorry et al. VALUE IN HEALTH
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States
- (2017) Jingshu Wang et al. Journal of Managed Care & Specialty Pharmacy
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death
- (2014) Anthony J Hatswell et al. Health and Quality of Life Outcomes
- Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
- (2014) Patti Curl et al. PLoS One
- Melanoma Treatment Costs
- (2012) Gery P. Guy et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Elicitation of health state utilities in neuroendocrine tumours
- (2012) P. Swinburn et al. JOURNAL OF MEDICAL ECONOMICS
- Improved curve fits to summary survival data: application to economic evaluation of health technologies
- (2011) Martin W Hoyle et al. BMC Medical Research Methodology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started